Skip to main content

Table 2 ERG’s Maximum b-wave amplitude and semi saturation constant from the rabbits treated with PRO-169 and Ranibizumab intravitreal injections

From: Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits

  Experimental eye Control eye Vmax ratio δ Log σ
Vmax (µV) Log σ (cd s/m2) Vmax (µV) Log σ (cd s/m2)
PRO-169
 1 month 128.747 − 2.626 154.359 − 2.253 0.879 − 0.373
 2 months 276.490 − 2.313 266.438 − 2.353 1.031 0.040
 3 months 286.428 − 2.473 238.032 − 2.756 1.050 0.094
Ranibizumab
 1 month 135.376 − 2.177 136.858 − 2.218 1.007 0.041
 2 months 268.382 − 2.468 299.659 − 2.332 0.907 − 0.136
 3 months 241.647 − 2.696 229.543 − 2.760 1.118 0.064
  1. Medium values. No significant differences between experimental (OD) and control eyes (OS) and between groups (injected eyes), in all comparisons, p > 0.05 (Mann–Whitney U test), n = 4 NWZ rabbit’s eyes per group